Delphia (USA)’s Kyntra Bio KYNB Stock Holding History

Delphia (USA)’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-577	Closed	-$203K	–	350
2021 Q4	$203K	Buy	+577	New	+$180K	0.22%	218

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Delphia (USA)'s KYNB Position: Q1 2022 in Review

Delphia (USA) sold out of Kyntra Bio (KYNB) in Q1 2022, closing a stake of 577 shares — an estimated $203K sold.

Delphia (USA) first reported a position in KYNB in Q4 2021 and held it in 1 quarter. The position peaked at $203K in Q4 2021. 156 funds tracked by Wall St. Rank hold KYNB as of Q1 2022.

Delphia (USA) reported no remaining Kyntra Bio position as of Q1 2022 after selling out during the quarter.
Delphia (USA) sold 577 Kyntra Bio shares in Q1 2022, an estimated $203K.
Delphia (USA) first reported a position in Kyntra Bio in Q4 2021 and held it in 1 quarter.
Delphia (USA)'s Kyntra Bio position peaked at $203K in Q4 2021.
156 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2022.

Based on Delphia (USA)'s 13F filing for Q1 2022, filed 16 May 2022.